MGMT inhibitor Lomeguatrib Small Molecule (Tool Compound)

The MGMT inhibitor Lomeguatrib is a potent inhibitor of O6-alklguanine-DNA-alkyltransferase. It shows antitumoral activity in vivo in combination with the compound Temozolomide.

Contributors

Inventor	Institute
Geoffrey Margison	Cancer Research UK, Manchester Institute

Cat. #:	151711
Tool sub type:	Inhibitor
Research Fields:	Cell signaling and signal transduction
Application:	Lomeguatrib (20 mg/kg/day for 5 days) combined with Temozolomide (100 mg/kg/day for 5 days) produces a substantial tumour growth delay: median tumour quintupling time is increased by 22 days without any significant increase in toxicity, while neither of the two drugs administrated along show any antitumor activity. Lomeguatrib inactivates ATase and enhances the anti-tumour effect of Temozolomide in A375M human melanoma xenografts model. Lomeguatrib, at a single dose of 20 mg/kg i.p., produces…
Purpose:	Inhibitor

Alternate name:	PaTrin 2
Product description:	The MGMT inhibitor Lomeguatrib is a potent inhibitor of O6-alklguanine-DNA-alkyltransferase. It shows antitumoral activity in vivo in combination with the compound Temozolomide.
Molecular weight:	326.17

Primary target:	DNA repair protein MGMT and related mammalian proteins

Storage conditions:	Ambient
Shipping conditions:	Dry Ice

References:	Barvaux et al. 2004. Mol Cancer Ther. 3: 1215-20 (PMID: 15426188) Clemons et al. 2005. Br J Cancer. 93: 1152-6 (PMID: 16278661) Ranson et al. 2006. Clin Cancer Res. 12: 1577-84 (PMID: 16533784) Khan et al. 2008 Br J Cancer. 98: 1614-8 (PMID: 18475294) Watson et al. 2010. Clin Cancer Res. 16: 743-9 (20068091)

Unfortunately this tool is not currently available through our online checkout process. Please contact our team directly to obtain further information on accessing this tool.

Enquire about this Tool

If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Request a license

Get support

New to CancerTools?

We are a trusted, non-profit platform for cancer research products, part of Cancer Research UK – by sourcing your cancer research tools from us you help fund future cancer research.

Find out more

Related Tools for Small molecules

Cat. #

Tool Name

151831

Protein Kinase D inhibitor CRT0066101 Small Molecule (Tool Compound)

Key Info

Cat. #:	151831
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	In Panc-1 subcutaneous xenograft model, orally administration of CRT0066101 at the dosage of 80 mg/kg/d for 24 days significantly suppressed pancreatic cancer growth. Moreover, when CRT0066101 reached its peak concentration (12 Îźmol/L) in tumor model, the expression of activated PKD1/2 in the treated tumor explants was substantially decreased. It was concluded that CRT0066101 given orally at 80 mg/kg/d for 21 days in Panc-1 orthotropic model suppressed tumor growth potently in vivo. Clinical…

View Tool

151839

Antitumoral Phortress Small Molecule (Tool Compound)

Key Info

Cat. #:	151839
Sub-type:	Antitumoral
Availability:	Please enquire for quantities and pricing
Application:	Active against breast, ovarian and renal carcinomas. Taken up into sensitive cells followed by aryl hydrocarbon receptor binding and translocation into the nucleus. Requires metabolic activation by cytochrome P450 to generate cytotoxic species. Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells.

View Tool

151843

AKR1C3 inhibitor CRT0036521 Small Molecule (Tool Compound)

Key Info

Cat. #:	151843
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The compounds showed good cellular potency, as measured by inhibition of AKR1C3 metabolism of a known dinitrobenzamide substrate, with a broad rank order between enzymic and cellular activity, but amide analogues were more effective than predicted by the cellular assay. displays potency in a cellular assay, blocking the ability of AKR1C3 to metabolize a proven substrate.

View Tool

152754

CDK2 inhibitor NU6301 Small Molecule (Tool Compound)

Key Info

Cat. #:	152754
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The prodrug NU6301 rapidly generated NU6102 in vitro in mouse plasma, and tumour NU6102 levels in vivo consistent with activity in vitro. Eight or 12 hourly dosing of 120 mg/kg NU6301 for 10 days was well tolerated in SKUT-1B tumour-bearing mice and inhibited Rb phosphorylation in tumour tissue. Two (8 hourly dosing) and 3 (12 hourly dosing) day tumour growth delay was observed (p=0.04 and p=0.007, respectively) following NU6301 administration. NU6102 selectively inhibited the growth of CDK2 WT (wild type) versus KO MEFs (knockout mouse embryo fibroblasts) (GIââ (concentration required to inhibit cell growth by 50%) 14 ÎźM versus >30 ÎźM), and was more growth-inhibitory in p53 mutant or null versus p53 WT cells (p=0.02), and in Rb (retinoblastoma protein) WT SKUT-1B versus SKUT 1 Rb deficient cells (p=0.01). In SKUT-1B cells NU6102 induced a G2 arrest, inhibition of Rb phosphorylation and cytotoxicity (LCââ 2.6 ÎźM for a 24h exposure).

View Tool

152788

Phosphatidylinositol-4-phosphate 5-kinase inhibitor PIP5K Small Molecule (Collaborative Toolkit)

Key Info

Cat. #:	152788
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing

View Tool

By Category

By Cancer Type

More

MGMT inhibitor Lomeguatrib Small Molecule (Tool Compound)

Contributors

Related Tools for Small molecules

Tool enquiry